Bifikafusp alfa

Names

[ CAS No. ]:
1957239-90-5

[ Name ]:
Bifikafusp alfa

Biological Activity

[Description]:

Bifikafusp alfa (L19-IL2) is an immunotherapy fusion protein consisting of human L19 antibodies fused to the human cytokine interleukin 2 (IL2).Bifikafusp alfa is specific to the EDB domain of fibronectin. Bifikafusp alfa has anticancer activity[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

[In Vivo]

Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; 雌性 NMRI 裸鼠 MiaPaca-A2 异种移植) 对已建立的胰腺癌具有抗肿瘤活性[1]。 Animal Model: Female NMRI nude mice with MiaPaca-A2 xenografts[1] Dosage: 1.43 and 4.29 MIU/kg Administration: Intraperitoneal injection; daily; for 10 days Result: Reduced tumor volume to 21.4% (1.43 MIU/kg) and 2.7% (4.29 MIU/kg) compared with control mice.

[References]

[1]. Wagner K, et, al. The targeted immunocytokine L19-IL2 efficiently inhibits the growth of orthotopic pancreatic cancer. Clin Cancer Res. 2008 Aug 1;14(15):4951-60.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.